基因组分型分类器在中危前列腺癌中的表现:NRG Oncology/RTOG 0126 随机 3 期试验结果
该辅助研究纳入 NRG Oncology/RTOG 0126 随机 3 期试验中 215 例中危前列腺癌患者标本,评估 22 基因 Decipher 基因组分类器(GC)的预后与预测价值。中位随访 12.8 年,GC 每增加 0.1 单位与疾病进展、生化失败、远处转移及前列腺癌特异性死亡独立相关;GC 低危与高危患者 10 年远处转移率分别为 4% 与 16%。
要点
- 22 基因 GC 每 0.1 单位与疾病进展 sHR 1.12、生化失败 sHR 1.22、远处转移 sHR 1.28、前列腺癌特异性死亡 sHR 1.45 独立相关。
- GC 低危患者 10 年远处转移为 4%,GC 高危患者为 16%。
- GC 低评分患者两放疗组 10 年无转移生存率差异为 -7%,GC 高评分患者为 21%(交互作用 P=0.04)。
核心结论
- 该研究首次利用中危前列腺癌随机 3 期试验数据验证活检基因表达分类器的预后与预测价值,Decipher 可改善风险分层并辅助治疗决策。
研究设计与样本
- NRG Oncology/RTOG 0126 随机 3 期试验的辅助项目,入组中危前列腺癌患者随机接受 70.2 Gy 或 79.2 Gy 放疗且未用雄激素剥夺治疗,从最高级别肿瘤灶提取 RNA 构建锁定的 22 基因 GC 模型,215 例样本通过质控纳入分析。
主要发现
- 中位随访 12.8 年(范围 2.4-17.7 年),多变量分析显示 22 基因 GC(每 0.1 单位)对疾病进展 sHR 1.12(95%CI 1.00-1.26,P=0.04)、生化失败 sHR 1.22(95%CI 1.10-1.37,P<0.001)、远处转移 sHR 1.28(95%CI 1.06-1.55,P=0.01)及前列腺癌特异性死亡 sHR 1.45(95%CI 1.20-1.76,P<0.001)独立预后。
- GC 低危患者 10 年远处转移为 4%,GC 高危患者为 16%。
- GC 低评分患者两放疗组 10 年无转移生存率差异为 -7%,GC 高评分患者为 21%(交互作用 P=0.04)。
关键数值与推荐
- 22 基因 GC 每 0.1 单位与疾病进展 sHR 1.12(95%CI 1.00-1.26,P=0.04)独立相关。
- 22 基因 GC 每 0.1 单位与生化失败 sHR 1.22(95%CI 1.10-1.37,P<0.001)独立相关。
- 22 基因 GC 每 0.1 单位与远处转移 sHR 1.28(95%CI 1.06-1.55,P=0.01)独立相关。
- 22 基因 GC 每 0.1 单位与前列腺癌特异性死亡 sHR 1.45(95%CI 1.20-1.76,P<0.001)独立相关。
- GC 低危与高危患者 10 年远处转移分别为 4% 与 16%;GC 低评分与高评分患者两放疗组 10 年无转移生存率差异分别为 -7% 与 21%(交互作用 P=0.04)。
临床怎么用
- Decipher 可改善中危前列腺癌患者风险分层并辅助治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up. METHODS AND MATERIALS: After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillary project was disease progression (composite of biochemical failure, local failure, distant metastasis, prostate cancer-specific mortality, and use of salvage therapy). Individual endpoints were also assessed. Fine-Gray or cause-specific Cox multivariable models were constructed adjusting for randomization arm and trial stratification factors. RESULTS: Two-hundred fifteen patient samples passed quality control for analysis. The median follow-up was 12.8 years (range, 2.4-17.7). On multivariable analysis, the 22-gene GC (per 0.1 unit) was independently prognostic for disease progression (subdistribution hazard ratio [sHR], 1.12; 95% confidence interval [CI], 1.00-1.26; P = .04), biochemical failure (sHR, 1.22; 95% CI, 1.10-1.37; P < .001), distant metastasis (sHR, 1.28; 95% CI, 1.06-1.55; P = .01), and prostate cancer-specific mortality (sHR, 1.45; 95% CI, 1.20-1.76; P < .001). Ten-year distant metastasis in GC low-risk patients was 4% compared with 16% for GC high-risk patients. In patients with lower GC scores, the 10-year difference in metastasis-free survival rate between arms was -7%, compared with 21% for higher GC patients (P-interaction = .04). CONCLUSIONS: This study represents the first validation of a biopsy-based gene expression classifier, assessing both its prognostic and predictive value, using data from a randomized phase 3 trial of intermediate-risk prostate cancer. Decipher improves risk stratification and can aid in treatment decision-making in men with intermediate-risk disease.
引用
- Spratt DE, Liu VYT, Michalski J, et al. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37137444. doi:10.1016/j.ijrobp.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。